賈躍亭就法拉第未來(FFIE.US)FF91推遲交付致歉
法拉第未來(FFIE.US)宣佈FF 91 2.0 Futurist Alliance第二階段交付推遲到8月,創始人兼首席產品和用戶官賈躍亭發文致歉,表示第二階段交付推遲反映出團隊的工業化能力和融資能力都有待提升,承諾若解決相關問題,將盡快啓動第二階段交付。
他又指,過去一年中連續幾個季度公司都擁有低現金餘額,可以見到法拉第未來極度緊張的資金狀況,已嚴重傷害到發展戰略的快速推進,認爲必須徹底解決資金問題才能保持公司價值在上升高速通道上繼續前進,因此在與大型機構投資人和財務顧問進行諮詢和溝通後,決定採取並股及擴股相關舉措,以解決公司股價過低、可發行股數不足及股份註冊需時過長的三大融資技術瓶頸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.